nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—HTR2C—Sorafenib—kidney cancer	0.0778	0.139	CbGbCtD
Atomoxetine—CYP2D6—Temsirolimus—kidney cancer	0.0765	0.137	CbGbCtD
Atomoxetine—CYP3A4—Everolimus—kidney cancer	0.0721	0.129	CbGbCtD
Atomoxetine—CYP3A4—Temsirolimus—kidney cancer	0.0487	0.0868	CbGbCtD
Atomoxetine—CYP2D6—Pazopanib—kidney cancer	0.0402	0.0717	CbGbCtD
Atomoxetine—CYP2C19—Sorafenib—kidney cancer	0.0307	0.0547	CbGbCtD
Atomoxetine—CYP2D6—Erlotinib—kidney cancer	0.0287	0.0512	CbGbCtD
Atomoxetine—CYP3A4—Pazopanib—kidney cancer	0.0256	0.0456	CbGbCtD
Atomoxetine—CYP2D6—Sorafenib—kidney cancer	0.0233	0.0416	CbGbCtD
Atomoxetine—CYP2D6—Vinblastine—kidney cancer	0.023	0.0411	CbGbCtD
Atomoxetine—CYP3A4—Erlotinib—kidney cancer	0.0182	0.0325	CbGbCtD
Atomoxetine—CYP3A4—Paclitaxel—kidney cancer	0.0167	0.0298	CbGbCtD
Atomoxetine—CYP3A4—Sorafenib—kidney cancer	0.0148	0.0265	CbGbCtD
Atomoxetine—CYP3A4—Vinblastine—kidney cancer	0.0146	0.0261	CbGbCtD
Atomoxetine—CYP3A4—Vincristine—kidney cancer	0.0144	0.0257	CbGbCtD
Atomoxetine—CYP2D6—Doxorubicin—kidney cancer	0.0142	0.0253	CbGbCtD
Atomoxetine—CYP3A4—Sunitinib—kidney cancer	0.012	0.0214	CbGbCtD
Atomoxetine—CYP3A4—Doxorubicin—kidney cancer	0.009	0.0161	CbGbCtD
Atomoxetine—CYP2C19—urine—kidney cancer	0.00274	0.153	CbGeAlD
Atomoxetine—NPY1R—renal system—kidney cancer	0.0021	0.117	CbGeAlD
Atomoxetine—NPY1R—cortex of kidney—kidney cancer	0.00198	0.11	CbGeAlD
Atomoxetine—NPY1R—gonad—kidney cancer	0.00188	0.105	CbGeAlD
Atomoxetine—HTR2A—urine—kidney cancer	0.00175	0.0978	CbGeAlD
Atomoxetine—CYP3A4—urine—kidney cancer	0.00162	0.0905	CbGeAlD
Atomoxetine—CYP2D6—urine—kidney cancer	0.0016	0.0891	CbGeAlD
Atomoxetine—Pseudoephedrine—IL2—kidney cancer	0.00142	0.193	CrCbGaD
Atomoxetine—Ephedrine—ACHE—kidney cancer	0.00111	0.151	CrCbGaD
Atomoxetine—HTR1D—kidney—kidney cancer	0.000834	0.0465	CbGeAlD
Atomoxetine—Ephedrine—BCHE—kidney cancer	0.00065	0.0888	CrCbGaD
Atomoxetine—SLC6A2—gonad—kidney cancer	0.00064	0.0357	CbGeAlD
Atomoxetine—Fenoprofen—PTGS1—kidney cancer	0.000545	0.0745	CrCbGaD
Atomoxetine—HTR2A—renal system—kidney cancer	0.000429	0.0239	CbGeAlD
Atomoxetine—HTR2A—kidney—kidney cancer	0.000414	0.0231	CbGeAlD
Atomoxetine—CYP3A4—renal system—kidney cancer	0.000397	0.0221	CbGeAlD
Atomoxetine—CYP2D6—renal system—kidney cancer	0.000391	0.0218	CbGeAlD
Atomoxetine—HTR2A—gonad—kidney cancer	0.000384	0.0214	CbGeAlD
Atomoxetine—CYP3A4—kidney—kidney cancer	0.000384	0.0214	CbGeAlD
Atomoxetine—Warfarin—CYP1A1—kidney cancer	0.000381	0.0521	CrCbGaD
Atomoxetine—CYP2D6—kidney—kidney cancer	0.000378	0.0211	CbGeAlD
Atomoxetine—Reboxetine—ABCB1—kidney cancer	0.000354	0.0484	CrCbGaD
Atomoxetine—Protriptyline—ABCB1—kidney cancer	0.000325	0.0445	CrCbGaD
Atomoxetine—Ketoprofen—PTGS1—kidney cancer	0.000322	0.0439	CrCbGaD
Atomoxetine—Fenoprofen—PTGS2—kidney cancer	0.000312	0.0426	CrCbGaD
Atomoxetine—Vomiting—Vinblastine—kidney cancer	0.000274	0.000768	CcSEcCtD
Atomoxetine—Dizziness—Erlotinib—kidney cancer	0.000274	0.000768	CcSEcCtD
Atomoxetine—Vomiting—Everolimus—kidney cancer	0.000273	0.000765	CcSEcCtD
Atomoxetine—Urethral disorder—Capecitabine—kidney cancer	0.000273	0.000765	CcSEcCtD
Atomoxetine—Paraesthesia—Vincristine—kidney cancer	0.000272	0.000763	CcSEcCtD
Atomoxetine—Agitation—Paclitaxel—kidney cancer	0.000271	0.00076	CcSEcCtD
Atomoxetine—Rash—Everolimus—kidney cancer	0.000271	0.000759	CcSEcCtD
Atomoxetine—Dermatitis—Everolimus—kidney cancer	0.00027	0.000758	CcSEcCtD
Atomoxetine—Headache—Vinblastine—kidney cancer	0.00027	0.000757	CcSEcCtD
Atomoxetine—Headache—Everolimus—kidney cancer	0.000269	0.000754	CcSEcCtD
Atomoxetine—Body temperature increased—Dactinomycin—kidney cancer	0.000268	0.000752	CcSEcCtD
Atomoxetine—Abdominal pain—Dactinomycin—kidney cancer	0.000268	0.000752	CcSEcCtD
Atomoxetine—Asthenia—Sorafenib—kidney cancer	0.000267	0.000749	CcSEcCtD
Atomoxetine—Vertigo—Paclitaxel—kidney cancer	0.000265	0.000743	CcSEcCtD
Atomoxetine—Syncope—Paclitaxel—kidney cancer	0.000265	0.000742	CcSEcCtD
Atomoxetine—Lethargy—Doxorubicin—kidney cancer	0.000265	0.000742	CcSEcCtD
Atomoxetine—Decreased appetite—Vincristine—kidney cancer	0.000264	0.000739	CcSEcCtD
Atomoxetine—Pruritus—Sorafenib—kidney cancer	0.000264	0.000739	CcSEcCtD
Atomoxetine—Vomiting—Erlotinib—kidney cancer	0.000263	0.000738	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000262	0.000735	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Vincristine—kidney cancer	0.000262	0.000734	CcSEcCtD
Atomoxetine—Fatigue—Vincristine—kidney cancer	0.000261	0.000733	CcSEcCtD
Atomoxetine—Rash—Erlotinib—kidney cancer	0.000261	0.000732	CcSEcCtD
Atomoxetine—Dermatitis—Erlotinib—kidney cancer	0.000261	0.000731	CcSEcCtD
Atomoxetine—Palpitations—Paclitaxel—kidney cancer	0.000261	0.000731	CcSEcCtD
Atomoxetine—Insomnia—Gemcitabine—kidney cancer	0.00026	0.000729	CcSEcCtD
Atomoxetine—Headache—Erlotinib—kidney cancer	0.000259	0.000727	CcSEcCtD
Atomoxetine—Loss of consciousness—Paclitaxel—kidney cancer	0.000259	0.000727	CcSEcCtD
Atomoxetine—Constipation—Vincristine—kidney cancer	0.000259	0.000727	CcSEcCtD
Atomoxetine—Pain—Vincristine—kidney cancer	0.000259	0.000727	CcSEcCtD
Atomoxetine—Paraesthesia—Gemcitabine—kidney cancer	0.000258	0.000724	CcSEcCtD
Atomoxetine—Flushing—Capecitabine—kidney cancer	0.000258	0.000724	CcSEcCtD
Atomoxetine—Cardiac disorder—Capecitabine—kidney cancer	0.000258	0.000724	CcSEcCtD
Atomoxetine—Cough—Paclitaxel—kidney cancer	0.000258	0.000722	CcSEcCtD
Atomoxetine—Asthenia—Sunitinib—kidney cancer	0.000257	0.000721	CcSEcCtD
Atomoxetine—Nortriptyline—PTGS1—kidney cancer	0.000257	0.0351	CrCbGaD
Atomoxetine—Nausea—Vinblastine—kidney cancer	0.000256	0.000718	CcSEcCtD
Atomoxetine—Somnolence—Gemcitabine—kidney cancer	0.000256	0.000717	CcSEcCtD
Atomoxetine—Convulsion—Paclitaxel—kidney cancer	0.000256	0.000717	CcSEcCtD
Atomoxetine—Propranolol—CYP1A1—kidney cancer	0.000255	0.0349	CrCbGaD
Atomoxetine—Affect lability—Doxorubicin—kidney cancer	0.000255	0.000715	CcSEcCtD
Atomoxetine—Nausea—Everolimus—kidney cancer	0.000255	0.000715	CcSEcCtD
Atomoxetine—Diarrhoea—Sorafenib—kidney cancer	0.000255	0.000715	CcSEcCtD
Atomoxetine—Pruritus—Sunitinib—kidney cancer	0.000254	0.000711	CcSEcCtD
Atomoxetine—Angiopathy—Capecitabine—kidney cancer	0.000252	0.000708	CcSEcCtD
Atomoxetine—Arthralgia—Paclitaxel—kidney cancer	0.000251	0.000704	CcSEcCtD
Atomoxetine—Chest pain—Paclitaxel—kidney cancer	0.000251	0.000704	CcSEcCtD
Atomoxetine—Myalgia—Paclitaxel—kidney cancer	0.000251	0.000704	CcSEcCtD
Atomoxetine—Mediastinal disorder—Capecitabine—kidney cancer	0.000251	0.000703	CcSEcCtD
Atomoxetine—Anxiety—Paclitaxel—kidney cancer	0.00025	0.000702	CcSEcCtD
Atomoxetine—Decreased appetite—Gemcitabine—kidney cancer	0.00025	0.000701	CcSEcCtD
Atomoxetine—Chills—Capecitabine—kidney cancer	0.00025	0.0007	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.00025	0.0007	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000248	0.000696	CcSEcCtD
Atomoxetine—Fatigue—Gemcitabine—kidney cancer	0.000248	0.000695	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Vincristine—kidney cancer	0.000248	0.000695	CcSEcCtD
Atomoxetine—Dizziness—Sorafenib—kidney cancer	0.000246	0.000691	CcSEcCtD
Atomoxetine—Constipation—Gemcitabine—kidney cancer	0.000246	0.00069	CcSEcCtD
Atomoxetine—Pain—Gemcitabine—kidney cancer	0.000246	0.00069	CcSEcCtD
Atomoxetine—Nausea—Erlotinib—kidney cancer	0.000246	0.00069	CcSEcCtD
Atomoxetine—Dry mouth—Paclitaxel—kidney cancer	0.000246	0.000689	CcSEcCtD
Atomoxetine—Mood swings—Doxorubicin—kidney cancer	0.000246	0.000688	CcSEcCtD
Atomoxetine—Diarrhoea—Sunitinib—kidney cancer	0.000245	0.000688	CcSEcCtD
Atomoxetine—Mental disorder—Capecitabine—kidney cancer	0.000244	0.000683	CcSEcCtD
Atomoxetine—Asthenia—Dactinomycin—kidney cancer	0.000244	0.000683	CcSEcCtD
Atomoxetine—Malnutrition—Capecitabine—kidney cancer	0.000242	0.000679	CcSEcCtD
Atomoxetine—Body temperature increased—Vincristine—kidney cancer	0.00024	0.000672	CcSEcCtD
Atomoxetine—Abdominal pain—Vincristine—kidney cancer	0.00024	0.000672	CcSEcCtD
Atomoxetine—Infection—Paclitaxel—kidney cancer	0.000239	0.000671	CcSEcCtD
Atomoxetine—Flatulence—Capecitabine—kidney cancer	0.000239	0.000669	CcSEcCtD
Atomoxetine—Diphenhydramine—PTGS1—kidney cancer	0.000237	0.0324	CrCbGaD
Atomoxetine—Dysgeusia—Capecitabine—kidney cancer	0.000237	0.000665	CcSEcCtD
Atomoxetine—Dizziness—Sunitinib—kidney cancer	0.000237	0.000665	CcSEcCtD
Atomoxetine—Feeling abnormal—Gemcitabine—kidney cancer	0.000237	0.000665	CcSEcCtD
Atomoxetine—Shock—Paclitaxel—kidney cancer	0.000237	0.000664	CcSEcCtD
Atomoxetine—Vomiting—Sorafenib—kidney cancer	0.000237	0.000664	CcSEcCtD
Atomoxetine—Abdominal pain upper—Doxorubicin—kidney cancer	0.000237	0.000664	CcSEcCtD
Atomoxetine—Nervous system disorder—Paclitaxel—kidney cancer	0.000236	0.000662	CcSEcCtD
Atomoxetine—Tachycardia—Paclitaxel—kidney cancer	0.000235	0.000659	CcSEcCtD
Atomoxetine—Rash—Sorafenib—kidney cancer	0.000235	0.000659	CcSEcCtD
Atomoxetine—Dermatitis—Sorafenib—kidney cancer	0.000235	0.000658	CcSEcCtD
Atomoxetine—Back pain—Capecitabine—kidney cancer	0.000234	0.000657	CcSEcCtD
Atomoxetine—Breast disorder—Doxorubicin—kidney cancer	0.000234	0.000657	CcSEcCtD
Atomoxetine—Skin disorder—Paclitaxel—kidney cancer	0.000234	0.000656	CcSEcCtD
Atomoxetine—Headache—Sorafenib—kidney cancer	0.000233	0.000654	CcSEcCtD
Atomoxetine—Muscle spasms—Capecitabine—kidney cancer	0.000233	0.000653	CcSEcCtD
Atomoxetine—Hyperhidrosis—Paclitaxel—kidney cancer	0.000233	0.000653	CcSEcCtD
Atomoxetine—Diarrhoea—Dactinomycin—kidney cancer	0.000232	0.000651	CcSEcCtD
Atomoxetine—Nasopharyngitis—Doxorubicin—kidney cancer	0.000232	0.00065	CcSEcCtD
Atomoxetine—Anorexia—Paclitaxel—kidney cancer	0.00023	0.000644	CcSEcCtD
Atomoxetine—Vision blurred—Capecitabine—kidney cancer	0.000228	0.00064	CcSEcCtD
Atomoxetine—Vomiting—Sunitinib—kidney cancer	0.000228	0.000639	CcSEcCtD
Atomoxetine—Body temperature increased—Gemcitabine—kidney cancer	0.000227	0.000638	CcSEcCtD
Atomoxetine—Tremor—Capecitabine—kidney cancer	0.000227	0.000636	CcSEcCtD
Atomoxetine—Rash—Sunitinib—kidney cancer	0.000226	0.000634	CcSEcCtD
Atomoxetine—Dermatitis—Sunitinib—kidney cancer	0.000226	0.000633	CcSEcCtD
Atomoxetine—Headache—Sunitinib—kidney cancer	0.000225	0.00063	CcSEcCtD
Atomoxetine—Influenza—Doxorubicin—kidney cancer	0.000224	0.000628	CcSEcCtD
Atomoxetine—Fluoxetine—ABCB1—kidney cancer	0.000222	0.0304	CrCbGaD
Atomoxetine—Nausea—Sorafenib—kidney cancer	0.000221	0.00062	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000219	0.000615	CcSEcCtD
Atomoxetine—Insomnia—Paclitaxel—kidney cancer	0.000218	0.000611	CcSEcCtD
Atomoxetine—Vertigo—Capecitabine—kidney cancer	0.000218	0.00061	CcSEcCtD
Atomoxetine—Asthenia—Vincristine—kidney cancer	0.000218	0.00061	CcSEcCtD
Atomoxetine—Syncope—Capecitabine—kidney cancer	0.000217	0.000609	CcSEcCtD
Atomoxetine—Paraesthesia—Paclitaxel—kidney cancer	0.000216	0.000606	CcSEcCtD
Atomoxetine—Vomiting—Dactinomycin—kidney cancer	0.000216	0.000605	CcSEcCtD
Atomoxetine—Somnolence—Paclitaxel—kidney cancer	0.000214	0.0006	CcSEcCtD
Atomoxetine—Palpitations—Capecitabine—kidney cancer	0.000214	0.0006	CcSEcCtD
Atomoxetine—Rash—Dactinomycin—kidney cancer	0.000214	0.0006	CcSEcCtD
Atomoxetine—Nausea—Sunitinib—kidney cancer	0.000213	0.000597	CcSEcCtD
Atomoxetine—Loss of consciousness—Capecitabine—kidney cancer	0.000213	0.000597	CcSEcCtD
Atomoxetine—Dyspepsia—Paclitaxel—kidney cancer	0.000212	0.000594	CcSEcCtD
Atomoxetine—Cough—Capecitabine—kidney cancer	0.000211	0.000592	CcSEcCtD
Atomoxetine—Dysuria—Doxorubicin—kidney cancer	0.000209	0.000587	CcSEcCtD
Atomoxetine—Decreased appetite—Paclitaxel—kidney cancer	0.000209	0.000587	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000208	0.000584	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000208	0.000583	CcSEcCtD
Atomoxetine—Fatigue—Paclitaxel—kidney cancer	0.000208	0.000582	CcSEcCtD
Atomoxetine—Maprotiline—ABCB1—kidney cancer	0.000208	0.0284	CrCbGaD
Atomoxetine—Diarrhoea—Vincristine—kidney cancer	0.000207	0.000582	CcSEcCtD
Atomoxetine—Pollakiuria—Doxorubicin—kidney cancer	0.000207	0.00058	CcSEcCtD
Atomoxetine—Asthenia—Gemcitabine—kidney cancer	0.000206	0.000579	CcSEcCtD
Atomoxetine—Chest pain—Capecitabine—kidney cancer	0.000206	0.000578	CcSEcCtD
Atomoxetine—Myalgia—Capecitabine—kidney cancer	0.000206	0.000578	CcSEcCtD
Atomoxetine—Arthralgia—Capecitabine—kidney cancer	0.000206	0.000578	CcSEcCtD
Atomoxetine—Constipation—Paclitaxel—kidney cancer	0.000206	0.000577	CcSEcCtD
Atomoxetine—Pain—Paclitaxel—kidney cancer	0.000206	0.000577	CcSEcCtD
Atomoxetine—Anxiety—Capecitabine—kidney cancer	0.000205	0.000576	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000205	0.000574	CcSEcCtD
Atomoxetine—Pruritus—Gemcitabine—kidney cancer	0.000204	0.000571	CcSEcCtD
Atomoxetine—Weight decreased—Doxorubicin—kidney cancer	0.000203	0.000568	CcSEcCtD
Atomoxetine—Dry mouth—Capecitabine—kidney cancer	0.000202	0.000565	CcSEcCtD
Atomoxetine—Nausea—Dactinomycin—kidney cancer	0.000202	0.000565	CcSEcCtD
Atomoxetine—Dizziness—Vincristine—kidney cancer	0.000201	0.000562	CcSEcCtD
Atomoxetine—Infestation NOS—Doxorubicin—kidney cancer	0.0002	0.00056	CcSEcCtD
Atomoxetine—Infestation—Doxorubicin—kidney cancer	0.0002	0.00056	CcSEcCtD
Atomoxetine—Feeling abnormal—Paclitaxel—kidney cancer	0.000198	0.000556	CcSEcCtD
Atomoxetine—Propafenone—ABCB1—kidney cancer	0.000198	0.0271	CrCbGaD
Atomoxetine—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000197	0.000552	CcSEcCtD
Atomoxetine—Diarrhoea—Gemcitabine—kidney cancer	0.000197	0.000552	CcSEcCtD
Atomoxetine—Infection—Capecitabine—kidney cancer	0.000196	0.000551	CcSEcCtD
Atomoxetine—Shock—Capecitabine—kidney cancer	0.000194	0.000545	CcSEcCtD
Atomoxetine—Conjunctivitis—Doxorubicin—kidney cancer	0.000194	0.000544	CcSEcCtD
Atomoxetine—Nervous system disorder—Capecitabine—kidney cancer	0.000194	0.000543	CcSEcCtD
Atomoxetine—Tachycardia—Capecitabine—kidney cancer	0.000193	0.000541	CcSEcCtD
Atomoxetine—Vomiting—Vincristine—kidney cancer	0.000193	0.000541	CcSEcCtD
Atomoxetine—Skin disorder—Capecitabine—kidney cancer	0.000192	0.000538	CcSEcCtD
Atomoxetine—Urticaria—Paclitaxel—kidney cancer	0.000191	0.000536	CcSEcCtD
Atomoxetine—Rash—Vincristine—kidney cancer	0.000191	0.000536	CcSEcCtD
Atomoxetine—Hyperhidrosis—Capecitabine—kidney cancer	0.000191	0.000536	CcSEcCtD
Atomoxetine—Dermatitis—Vincristine—kidney cancer	0.000191	0.000536	CcSEcCtD
Atomoxetine—Abdominal pain—Paclitaxel—kidney cancer	0.00019	0.000534	CcSEcCtD
Atomoxetine—Body temperature increased—Paclitaxel—kidney cancer	0.00019	0.000534	CcSEcCtD
Atomoxetine—Headache—Vincristine—kidney cancer	0.00019	0.000533	CcSEcCtD
Atomoxetine—Anorexia—Capecitabine—kidney cancer	0.000188	0.000528	CcSEcCtD
Atomoxetine—Sinusitis—Doxorubicin—kidney cancer	0.000187	0.000525	CcSEcCtD
Atomoxetine—Ketoprofen—PTGS2—kidney cancer	0.000184	0.0251	CrCbGaD
Atomoxetine—Vomiting—Gemcitabine—kidney cancer	0.000183	0.000513	CcSEcCtD
Atomoxetine—Rash—Gemcitabine—kidney cancer	0.000181	0.000509	CcSEcCtD
Atomoxetine—Dermatitis—Gemcitabine—kidney cancer	0.000181	0.000508	CcSEcCtD
Atomoxetine—Headache—Gemcitabine—kidney cancer	0.00018	0.000505	CcSEcCtD
Atomoxetine—Nausea—Vincristine—kidney cancer	0.00018	0.000505	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.00018	0.000505	CcSEcCtD
Atomoxetine—Insomnia—Capecitabine—kidney cancer	0.000179	0.000501	CcSEcCtD
Atomoxetine—Hypoaesthesia—Doxorubicin—kidney cancer	0.000178	0.0005	CcSEcCtD
Atomoxetine—Paraesthesia—Capecitabine—kidney cancer	0.000177	0.000498	CcSEcCtD
Atomoxetine—Urinary tract disorder—Doxorubicin—kidney cancer	0.000177	0.000497	CcSEcCtD
Atomoxetine—Urethral disorder—Doxorubicin—kidney cancer	0.000176	0.000493	CcSEcCtD
Atomoxetine—Dyspepsia—Capecitabine—kidney cancer	0.000174	0.000488	CcSEcCtD
Atomoxetine—Asthenia—Paclitaxel—kidney cancer	0.000173	0.000484	CcSEcCtD
Atomoxetine—Decreased appetite—Capecitabine—kidney cancer	0.000172	0.000482	CcSEcCtD
Atomoxetine—Nausea—Gemcitabine—kidney cancer	0.000171	0.000479	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000171	0.000478	CcSEcCtD
Atomoxetine—Fatigue—Capecitabine—kidney cancer	0.00017	0.000478	CcSEcCtD
Atomoxetine—Pruritus—Paclitaxel—kidney cancer	0.00017	0.000478	CcSEcCtD
Atomoxetine—Constipation—Capecitabine—kidney cancer	0.000169	0.000474	CcSEcCtD
Atomoxetine—Pain—Capecitabine—kidney cancer	0.000169	0.000474	CcSEcCtD
Atomoxetine—Flushing—Doxorubicin—kidney cancer	0.000166	0.000467	CcSEcCtD
Atomoxetine—Cardiac disorder—Doxorubicin—kidney cancer	0.000166	0.000467	CcSEcCtD
Atomoxetine—Diarrhoea—Paclitaxel—kidney cancer	0.000165	0.000462	CcSEcCtD
Atomoxetine—Feeling abnormal—Capecitabine—kidney cancer	0.000163	0.000457	CcSEcCtD
Atomoxetine—Angiopathy—Doxorubicin—kidney cancer	0.000163	0.000456	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Capecitabine—kidney cancer	0.000162	0.000453	CcSEcCtD
Atomoxetine—Mediastinal disorder—Doxorubicin—kidney cancer	0.000162	0.000453	CcSEcCtD
Atomoxetine—Chills—Doxorubicin—kidney cancer	0.000161	0.000451	CcSEcCtD
Atomoxetine—Dizziness—Paclitaxel—kidney cancer	0.000159	0.000447	CcSEcCtD
Atomoxetine—Mental disorder—Doxorubicin—kidney cancer	0.000157	0.00044	CcSEcCtD
Atomoxetine—Urticaria—Capecitabine—kidney cancer	0.000157	0.00044	CcSEcCtD
Atomoxetine—Abdominal pain—Capecitabine—kidney cancer	0.000156	0.000438	CcSEcCtD
Atomoxetine—Body temperature increased—Capecitabine—kidney cancer	0.000156	0.000438	CcSEcCtD
Atomoxetine—Malnutrition—Doxorubicin—kidney cancer	0.000156	0.000438	CcSEcCtD
Atomoxetine—Flatulence—Doxorubicin—kidney cancer	0.000154	0.000431	CcSEcCtD
Atomoxetine—Tension—Doxorubicin—kidney cancer	0.000153	0.000429	CcSEcCtD
Atomoxetine—Vomiting—Paclitaxel—kidney cancer	0.000153	0.000429	CcSEcCtD
Atomoxetine—Dysgeusia—Doxorubicin—kidney cancer	0.000153	0.000429	CcSEcCtD
Atomoxetine—Rash—Paclitaxel—kidney cancer	0.000152	0.000426	CcSEcCtD
Atomoxetine—Dermatitis—Paclitaxel—kidney cancer	0.000152	0.000425	CcSEcCtD
Atomoxetine—Nervousness—Doxorubicin—kidney cancer	0.000152	0.000425	CcSEcCtD
Atomoxetine—Back pain—Doxorubicin—kidney cancer	0.000151	0.000423	CcSEcCtD
Atomoxetine—Headache—Paclitaxel—kidney cancer	0.000151	0.000423	CcSEcCtD
Atomoxetine—Muscle spasms—Doxorubicin—kidney cancer	0.00015	0.000421	CcSEcCtD
Atomoxetine—Vision blurred—Doxorubicin—kidney cancer	0.000147	0.000412	CcSEcCtD
Atomoxetine—Agitation—Doxorubicin—kidney cancer	0.000143	0.000402	CcSEcCtD
Atomoxetine—Nausea—Paclitaxel—kidney cancer	0.000143	0.000401	CcSEcCtD
Atomoxetine—Asthenia—Capecitabine—kidney cancer	0.000142	0.000398	CcSEcCtD
Atomoxetine—Vertigo—Doxorubicin—kidney cancer	0.00014	0.000393	CcSEcCtD
Atomoxetine—Syncope—Doxorubicin—kidney cancer	0.00014	0.000392	CcSEcCtD
Atomoxetine—Pruritus—Capecitabine—kidney cancer	0.00014	0.000392	CcSEcCtD
Atomoxetine—Palpitations—Doxorubicin—kidney cancer	0.000138	0.000387	CcSEcCtD
Atomoxetine—Loss of consciousness—Doxorubicin—kidney cancer	0.000137	0.000385	CcSEcCtD
Atomoxetine—Cough—Doxorubicin—kidney cancer	0.000136	0.000382	CcSEcCtD
Atomoxetine—Propranolol—ABCB1—kidney cancer	0.000136	0.0185	CrCbGaD
Atomoxetine—Convulsion—Doxorubicin—kidney cancer	0.000135	0.000379	CcSEcCtD
Atomoxetine—Diarrhoea—Capecitabine—kidney cancer	0.000135	0.000379	CcSEcCtD
Atomoxetine—Chest pain—Doxorubicin—kidney cancer	0.000133	0.000373	CcSEcCtD
Atomoxetine—Arthralgia—Doxorubicin—kidney cancer	0.000133	0.000373	CcSEcCtD
Atomoxetine—Myalgia—Doxorubicin—kidney cancer	0.000133	0.000373	CcSEcCtD
Atomoxetine—Anxiety—Doxorubicin—kidney cancer	0.000132	0.000371	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000132	0.00037	CcSEcCtD
Atomoxetine—Dizziness—Capecitabine—kidney cancer	0.000131	0.000366	CcSEcCtD
Atomoxetine—Dry mouth—Doxorubicin—kidney cancer	0.00013	0.000364	CcSEcCtD
Atomoxetine—Infection—Doxorubicin—kidney cancer	0.000127	0.000355	CcSEcCtD
Atomoxetine—Vomiting—Capecitabine—kidney cancer	0.000126	0.000352	CcSEcCtD
Atomoxetine—Shock—Doxorubicin—kidney cancer	0.000125	0.000351	CcSEcCtD
Atomoxetine—Nervous system disorder—Doxorubicin—kidney cancer	0.000125	0.00035	CcSEcCtD
Atomoxetine—Rash—Capecitabine—kidney cancer	0.000125	0.000349	CcSEcCtD
Atomoxetine—Dermatitis—Capecitabine—kidney cancer	0.000125	0.000349	CcSEcCtD
Atomoxetine—Tachycardia—Doxorubicin—kidney cancer	0.000124	0.000349	CcSEcCtD
Atomoxetine—Headache—Capecitabine—kidney cancer	0.000124	0.000347	CcSEcCtD
Atomoxetine—Skin disorder—Doxorubicin—kidney cancer	0.000124	0.000347	CcSEcCtD
Atomoxetine—Hyperhidrosis—Doxorubicin—kidney cancer	0.000123	0.000345	CcSEcCtD
Atomoxetine—Anorexia—Doxorubicin—kidney cancer	0.000121	0.00034	CcSEcCtD
Atomoxetine—Nausea—Capecitabine—kidney cancer	0.000117	0.000329	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000116	0.000325	CcSEcCtD
Atomoxetine—Insomnia—Doxorubicin—kidney cancer	0.000115	0.000323	CcSEcCtD
Atomoxetine—Paraesthesia—Doxorubicin—kidney cancer	0.000114	0.000321	CcSEcCtD
Atomoxetine—Somnolence—Doxorubicin—kidney cancer	0.000113	0.000318	CcSEcCtD
Atomoxetine—Dyspepsia—Doxorubicin—kidney cancer	0.000112	0.000314	CcSEcCtD
Atomoxetine—Methadone—ABCB1—kidney cancer	0.000111	0.0152	CrCbGaD
Atomoxetine—Decreased appetite—Doxorubicin—kidney cancer	0.000111	0.000311	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.00011	0.000308	CcSEcCtD
Atomoxetine—Fatigue—Doxorubicin—kidney cancer	0.00011	0.000308	CcSEcCtD
Atomoxetine—Constipation—Doxorubicin—kidney cancer	0.000109	0.000305	CcSEcCtD
Atomoxetine—Pain—Doxorubicin—kidney cancer	0.000109	0.000305	CcSEcCtD
Atomoxetine—Feeling abnormal—Doxorubicin—kidney cancer	0.000105	0.000294	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000104	0.000292	CcSEcCtD
Atomoxetine—Desipramine—ABCB1—kidney cancer	0.000103	0.014	CrCbGaD
Atomoxetine—Urticaria—Doxorubicin—kidney cancer	0.000101	0.000284	CcSEcCtD
Atomoxetine—Body temperature increased—Doxorubicin—kidney cancer	0.000101	0.000282	CcSEcCtD
Atomoxetine—Abdominal pain—Doxorubicin—kidney cancer	0.000101	0.000282	CcSEcCtD
Atomoxetine—Asthenia—Doxorubicin—kidney cancer	9.14e-05	0.000256	CcSEcCtD
Atomoxetine—Pruritus—Doxorubicin—kidney cancer	9.01e-05	0.000253	CcSEcCtD
Atomoxetine—Diarrhoea—Doxorubicin—kidney cancer	8.72e-05	0.000244	CcSEcCtD
Atomoxetine—Dizziness—Doxorubicin—kidney cancer	8.42e-05	0.000236	CcSEcCtD
Atomoxetine—Vomiting—Doxorubicin—kidney cancer	8.1e-05	0.000227	CcSEcCtD
Atomoxetine—Rash—Doxorubicin—kidney cancer	8.03e-05	0.000225	CcSEcCtD
Atomoxetine—Dermatitis—Doxorubicin—kidney cancer	8.03e-05	0.000225	CcSEcCtD
Atomoxetine—Headache—Doxorubicin—kidney cancer	7.98e-05	0.000224	CcSEcCtD
Atomoxetine—Nausea—Doxorubicin—kidney cancer	7.57e-05	0.000212	CcSEcCtD
Atomoxetine—CYP2D6—Metabolism—CA9—kidney cancer	1.69e-05	0.000293	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—RAF1—kidney cancer	1.68e-05	0.000292	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—RAF1—kidney cancer	1.67e-05	0.00029	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—IL2—kidney cancer	1.66e-05	0.000289	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—POMC—kidney cancer	1.66e-05	0.000288	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—IL2—kidney cancer	1.65e-05	0.000287	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—RAF1—kidney cancer	1.64e-05	0.000284	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—JUNB—kidney cancer	1.63e-05	0.000283	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PAK1—kidney cancer	1.63e-05	0.000283	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—IL2—kidney cancer	1.62e-05	0.000281	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PIK3CA—kidney cancer	1.6e-05	0.000279	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APRT—kidney cancer	1.59e-05	0.000276	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—FH—kidney cancer	1.59e-05	0.000276	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PSMD7—kidney cancer	1.57e-05	0.000273	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TSC1—kidney cancer	1.57e-05	0.000273	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ANXA1—kidney cancer	1.57e-05	0.000273	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CRABP1—kidney cancer	1.56e-05	0.000271	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TP53—kidney cancer	1.55e-05	0.00027	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FLT1—kidney cancer	1.52e-05	0.000265	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL2—kidney cancer	1.51e-05	0.000262	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—POMC—kidney cancer	1.5e-05	0.000261	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL2—kidney cancer	1.5e-05	0.00026	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GPC3—kidney cancer	1.49e-05	0.00026	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL2—kidney cancer	1.47e-05	0.000255	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CA2—kidney cancer	1.45e-05	0.000253	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ITPR2—kidney cancer	1.45e-05	0.000252	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HIF1A—kidney cancer	1.44e-05	0.00025	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—POMC—kidney cancer	1.44e-05	0.00025	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TSC2—kidney cancer	1.43e-05	0.000249	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CRABP1—kidney cancer	1.43e-05	0.000249	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HIF1A—kidney cancer	1.43e-05	0.000248	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TSC2—kidney cancer	1.42e-05	0.000247	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALAD—kidney cancer	1.42e-05	0.000246	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—JUNB—kidney cancer	1.41e-05	0.000246	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PAK1—kidney cancer	1.41e-05	0.000246	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HIF1A—kidney cancer	1.4e-05	0.000243	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TSC2—kidney cancer	1.39e-05	0.000242	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.38e-05	0.00024	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KDR—kidney cancer	1.38e-05	0.000239	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KDR—kidney cancer	1.37e-05	0.000237	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.35e-05	0.000235	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KDR—kidney cancer	1.34e-05	0.000232	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.34e-05	0.000232	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ITPR2—kidney cancer	1.33e-05	0.000231	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF2—kidney cancer	1.33e-05	0.000231	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDKN2B—kidney cancer	1.32e-05	0.00023	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ACHE—kidney cancer	1.32e-05	0.000229	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTT1—kidney cancer	1.32e-05	0.000229	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—POMC—kidney cancer	1.31e-05	0.000227	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PGK1—kidney cancer	1.3e-05	0.000225	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC5A3—kidney cancer	1.3e-05	0.000225	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF1R—kidney cancer	1.29e-05	0.000224	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LDHB—kidney cancer	1.27e-05	0.000221	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—APC—kidney cancer	1.27e-05	0.00022	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KIT—kidney cancer	1.27e-05	0.00022	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—APC—kidney cancer	1.26e-05	0.000218	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KIT—kidney cancer	1.26e-05	0.000218	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SCARB1—kidney cancer	1.25e-05	0.000217	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—RAF1—kidney cancer	1.24e-05	0.000215	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS1—kidney cancer	1.24e-05	0.000215	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KIT—kidney cancer	1.23e-05	0.000214	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—APC—kidney cancer	1.23e-05	0.000214	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—IL2—kidney cancer	1.22e-05	0.000213	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ACHE—kidney cancer	1.21e-05	0.000211	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTT1—kidney cancer	1.21e-05	0.000211	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PSMD7—kidney cancer	1.21e-05	0.000211	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—MAPK3—kidney cancer	1.21e-05	0.000211	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—POMC—kidney cancer	1.21e-05	0.00021	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—MAPK3—kidney cancer	1.2e-05	0.000209	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—POMC—kidney cancer	1.2e-05	0.000208	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—BRAF—kidney cancer	1.19e-05	0.000207	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—BRAF—kidney cancer	1.18e-05	0.000205	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—MAPK3—kidney cancer	1.18e-05	0.000205	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—POMC—kidney cancer	1.17e-05	0.000204	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—BRAF—kidney cancer	1.16e-05	0.000201	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF2—kidney cancer	1.16e-05	0.000201	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—MAPK1—kidney cancer	1.15e-05	0.000201	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN2B—kidney cancer	1.15e-05	0.0002	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—BCHE—kidney cancer	1.15e-05	0.0002	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SCARB1—kidney cancer	1.15e-05	0.0002	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—MAPK1—kidney cancer	1.15e-05	0.000199	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS1—kidney cancer	1.14e-05	0.000198	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SLC5A5—kidney cancer	1.14e-05	0.000197	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—MAPK1—kidney cancer	1.12e-05	0.000195	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF1R—kidney cancer	1.12e-05	0.000194	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PSMD7—kidney cancer	1.12e-05	0.000194	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL2—kidney cancer	1.11e-05	0.000193	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—PIK3CA—kidney cancer	1.1e-05	0.000192	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CA9—kidney cancer	1.1e-05	0.000191	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SLC2A1—kidney cancer	1.1e-05	0.000191	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—PIK3CA—kidney cancer	1.09e-05	0.00019	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—KRAS—kidney cancer	1.09e-05	0.000189	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—KRAS—kidney cancer	1.08e-05	0.000188	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—RAF1—kidney cancer	1.08e-05	0.000187	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—PIK3CA—kidney cancer	1.07e-05	0.000186	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.06e-05	0.000185	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—IL2—kidney cancer	1.06e-05	0.000185	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—KRAS—kidney cancer	1.06e-05	0.000184	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HIF1A—kidney cancer	1.06e-05	0.000184	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—BCHE—kidney cancer	1.06e-05	0.000184	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TSC2—kidney cancer	1.06e-05	0.000184	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC5A5—kidney cancer	1.05e-05	0.000182	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KDR—kidney cancer	1.01e-05	0.000176	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC2A1—kidney cancer	1.01e-05	0.000175	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PIK3CA—kidney cancer	1e-05	0.000174	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RAF1—kidney cancer	9.94e-06	0.000173	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PIK3CA—kidney cancer	9.94e-06	0.000173	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RELA—kidney cancer	9.9e-06	0.000172	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RAF1—kidney cancer	9.87e-06	0.000171	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ERBB2—kidney cancer	9.84e-06	0.000171	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RELA—kidney cancer	9.83e-06	0.000171	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ERBB2—kidney cancer	9.76e-06	0.00017	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PIK3CA—kidney cancer	9.74e-06	0.000169	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MTOR—kidney cancer	9.71e-06	0.000169	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RAF1—kidney cancer	9.66e-06	0.000168	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL2—kidney cancer	9.65e-06	0.000168	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MTOR—kidney cancer	9.64e-06	0.000167	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RELA—kidney cancer	9.62e-06	0.000167	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ERBB2—kidney cancer	9.56e-06	0.000166	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MTOR—kidney cancer	9.43e-06	0.000164	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CRABP1—kidney cancer	9.37e-06	0.000163	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KIT—kidney cancer	9.33e-06	0.000162	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APC—kidney cancer	9.33e-06	0.000162	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	9.29e-06	0.000161	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HIF1A—kidney cancer	9.2e-06	0.00016	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TSC2—kidney cancer	9.17e-06	0.000159	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTP1—kidney cancer	9.15e-06	0.000159	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CDKN1B—kidney cancer	9.11e-06	0.000158	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CDKN1B—kidney cancer	9.04e-06	0.000157	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—MAPK3—kidney cancer	8.94e-06	0.000155	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL2—kidney cancer	8.92e-06	0.000155	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—POMC—kidney cancer	8.88e-06	0.000154	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CDKN1B—kidney cancer	8.85e-06	0.000154	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL2—kidney cancer	8.85e-06	0.000154	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KDR—kidney cancer	8.8e-06	0.000153	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—BRAF—kidney cancer	8.77e-06	0.000152	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ITPR2—kidney cancer	8.71e-06	0.000151	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCND1—kidney cancer	8.69e-06	0.000151	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—JUN—kidney cancer	8.67e-06	0.000151	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ABCB1—kidney cancer	8.66e-06	0.000151	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL2—kidney cancer	8.66e-06	0.000151	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCND1—kidney cancer	8.63e-06	0.00015	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—JUN—kidney cancer	8.61e-06	0.00015	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CTNNB1—kidney cancer	8.61e-06	0.00015	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CTNNB1—kidney cancer	8.54e-06	0.000148	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—MAPK1—kidney cancer	8.5e-06	0.000148	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCND1—kidney cancer	8.45e-06	0.000147	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—JUN—kidney cancer	8.43e-06	0.000146	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTP1—kidney cancer	8.42e-06	0.000146	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTM1—kidney cancer	8.41e-06	0.000146	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTEN—kidney cancer	8.39e-06	0.000146	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CTNNB1—kidney cancer	8.36e-06	0.000145	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTEN—kidney cancer	8.33e-06	0.000145	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTEN—kidney cancer	8.15e-06	0.000142	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—PIK3CA—kidney cancer	8.13e-06	0.000141	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KIT—kidney cancer	8.1e-06	0.000141	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APC—kidney cancer	8.1e-06	0.000141	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—KRAS—kidney cancer	8.03e-06	0.00014	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP1A1—kidney cancer	7.97e-06	0.000139	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ABCB1—kidney cancer	7.97e-06	0.000138	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ACHE—kidney cancer	7.94e-06	0.000138	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTT1—kidney cancer	7.94e-06	0.000138	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—MAPK3—kidney cancer	7.76e-06	0.000135	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTM1—kidney cancer	7.74e-06	0.000134	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—POMC—kidney cancer	7.71e-06	0.000134	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—BRAF—kidney cancer	7.62e-06	0.000132	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—kidney cancer	7.58e-06	0.000132	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—kidney cancer	7.52e-06	0.000131	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SCARB1—kidney cancer	7.52e-06	0.000131	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS1—kidney cancer	7.44e-06	0.000129	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—MAPK1—kidney cancer	7.38e-06	0.000128	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PIK3CA—kidney cancer	7.38e-06	0.000128	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—kidney cancer	7.36e-06	0.000128	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP1A1—kidney cancer	7.33e-06	0.000127	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RAF1—kidney cancer	7.32e-06	0.000127	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PSMD7—kidney cancer	7.3e-06	0.000127	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RELA—kidney cancer	7.29e-06	0.000127	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ERBB2—kidney cancer	7.25e-06	0.000126	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK3—kidney cancer	7.17e-06	0.000125	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MTOR—kidney cancer	7.15e-06	0.000124	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK3—kidney cancer	7.11e-06	0.000124	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PIK3CA—kidney cancer	7.06e-06	0.000123	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—KRAS—kidney cancer	6.97e-06	0.000121	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MYC—kidney cancer	6.97e-06	0.000121	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK3—kidney cancer	6.97e-06	0.000121	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MYC—kidney cancer	6.92e-06	0.00012	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—BCHE—kidney cancer	6.92e-06	0.00012	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC5A5—kidney cancer	6.83e-06	0.000119	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK1—kidney cancer	6.82e-06	0.000118	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MYC—kidney cancer	6.77e-06	0.000118	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK1—kidney cancer	6.77e-06	0.000118	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	6.71e-06	0.000117	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK1—kidney cancer	6.63e-06	0.000115	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC2A1—kidney cancer	6.6e-06	0.000115	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL2—kidney cancer	6.57e-06	0.000114	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.55e-06	0.000114	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KRAS—kidney cancer	6.44e-06	0.000112	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	6.41e-06	0.000111	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCND1—kidney cancer	6.4e-06	0.000111	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KRAS—kidney cancer	6.39e-06	0.000111	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—JUN—kidney cancer	6.39e-06	0.000111	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RAF1—kidney cancer	6.36e-06	0.00011	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	6.34e-06	0.00011	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RELA—kidney cancer	6.33e-06	0.00011	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ERBB2—kidney cancer	6.29e-06	0.000109	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KRAS—kidney cancer	6.26e-06	0.000109	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MTOR—kidney cancer	6.21e-06	0.000108	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTEN—kidney cancer	6.18e-06	0.000107	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—POMC—kidney cancer	5.95e-06	0.000103	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CA—kidney cancer	5.92e-06	0.000103	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CA—kidney cancer	5.87e-06	0.000102	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	5.83e-06	0.000101	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CA—kidney cancer	5.75e-06	9.99e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—kidney cancer	5.73e-06	9.95e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL2—kidney cancer	5.7e-06	9.91e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—kidney cancer	5.68e-06	9.87e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—kidney cancer	5.58e-06	9.69e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—kidney cancer	5.56e-06	9.67e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCND1—kidney cancer	5.56e-06	9.66e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—JUN—kidney cancer	5.55e-06	9.64e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	5.5e-06	9.56e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTP1—kidney cancer	5.5e-06	9.56e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—POMC—kidney cancer	5.47e-06	9.5e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTEN—kidney cancer	5.37e-06	9.32e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK3—kidney cancer	5.28e-06	9.17e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCB1—kidney cancer	5.21e-06	9.05e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MYC—kidney cancer	5.13e-06	8.92e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTM1—kidney cancer	5.06e-06	8.79e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK1—kidney cancer	5.02e-06	8.73e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—kidney cancer	4.85e-06	8.42e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP1A1—kidney cancer	4.8e-06	8.33e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KRAS—kidney cancer	4.74e-06	8.24e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—kidney cancer	4.74e-06	8.24e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK3—kidney cancer	4.58e-06	7.96e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MYC—kidney cancer	4.46e-06	7.75e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK1—kidney cancer	4.36e-06	7.58e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—kidney cancer	4.36e-06	7.58e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	4.36e-06	7.57e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—kidney cancer	4.22e-06	7.32e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTEN—kidney cancer	4.14e-06	7.18e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KRAS—kidney cancer	4.12e-06	7.16e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTEN—kidney cancer	3.8e-06	6.61e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	3.78e-06	6.58e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—kidney cancer	3.66e-06	6.36e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—POMC—kidney cancer	3.58e-06	6.21e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CA—kidney cancer	2.92e-06	5.07e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—kidney cancer	2.85e-06	4.95e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CA—kidney cancer	2.68e-06	4.66e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTEN—kidney cancer	2.49e-06	4.32e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.75e-06	3.05e-05	CbGpPWpGaD
